Long-term survival of patients with stage II and III gastric cancer who underwent gastrectomy with inadequate nodal assessment

Table 6 Overall survival Cox regression results for overall survival and cancer-specific survival after propensity score matching

	Overall survival				Cancer-specific survival
Variable	Univariable		Multivariable1		Univariable		Multivariable1
	HR (95%CI)	P value	HR (95%CI)	P value	HR (95%CI)	P value	HR (95%CI)	P value
Sex
Male	Reference				Reference
Female	0.98 (0.90-1.07)	0.662			1.03 (0.94-1.14)	0.517
Age
< 70	Reference				Reference
≥ 70	1.56 (1.43-1.71)	< 0.001			1.35 (1.23-1.49)	< 0.001
Race
White	Reference				Reference		Reference
Black	0.96 (0.85-1.08)	0.528	1.10 (0.97-1.24)	0.147	0.94 (0.83-1.08)	0.383	1.08 (0.94-1.23)	0.274
Asian/pacific	0.80 (0.72-0.89)	< 0.001	0.84 (0.75-0.93)	0.001	0.81 (0.72-0.90)	< 0.001	0.87 (0.77-0.97)	0.014
Insurance status
NA	Reference				Reference
Insured	0.87 (0.79-0.97)	0.009			0.87 (0.78-0.97)	0.013
Uninsured	0.99 (0.78-1.27)	0.972			0.96 (0.74-1.25)	0.754
Site of tumor
Fundus-body	Reference				Reference
Antrum-pylorus	1.07 (0.95-1.22)	0.275			1.11 (0.97-1.27)	0.140
Overlapping lesion of the stomach	1.33 (1.15-1.55)	< 0.001			1.39 (1.18-1.64)	< 0.001
Stomach, NOS	1.04 (0.92-1.18)	0.516			1.03 (0.90-1.19)	0.631
Histology
ADC, NOS	Reference				Reference		Reference
Signet ring cell carcinoma	1.26 (1.13-1.41)	< 0.001			1.37 (1.22-1.54)	< 0.001	1.22 (1.08-1.38)	0.001
ADC, instestinal type	0.89 (0.79-1.03)	0.114			0.81 (0.70-0.95)	0.008	0.91 (0.78-1.06)	0.238
Carcinoma, diffuse type	1.23(1.06-1.44)	0.008			1.29 (1.09-1.52)	0.003	1.18 (0.99-1.40)	0.054
ADC with mixed subtypes	1.15 (0.93-1.43)	0.193			1.28 (1.02-1.60)	0.032	1.13 (0.89-1.42)	0.318
Other	0.93 (0.77-1.13)	0.472			0.99 (0.81-1.21)	0.913	1.15 (0.93-1.41)	0.199
T stage, 8th ed
T1	Reference				Reference
T2	1.18 (0.83-1.67)	0.356			1.43 (0.91-2.24)	0.121
T3	1.85 (1.37-2.51)	< 0.001			2.60 (1.74-3.87)	< 0.001
T4a	2.84 (2.10-3.86)	< 0.001			4.28 (2.87-6.39)	< 0.001
T4b	3.44 (2.49-4.75)	< 0.001			5.13 (3.39-7.77)	< 0.001
N stage, 8th ed
N0	Reference				Reference
N1	1.09 (0.89-1.34)	0.380			1.08 (0.86-1.36)	0.518
N2	1.56 (1.31-1.87)	< 0.001			1.63 (1.33-1.99)	< 0.001
N3a	2.28 (1.93-2.69)	< 0.001			2.61 (2.16-3.16)	< 0.001
N3b	4.58 (3.91-5.37)	< 0.001			5.50 (4.59-6.58)	< 0.001
Stage, 8th ed
IIA	Reference		Reference		Reference		Reference
IIB	1.38 (1.12-1.70)	0.003	1.47 (1.18-1.81)	< 0.001	1.70 (1.33-2.18)	< 0.001	1.77 (1.38-2.29)	< 0.001
IIIA	1.96 (1.63-2.35)	< 0.001	2.21 (1.83-2.66)	< 0.001	2.39 (1.92-2.98)	< 0.001	2.66 (2.12-3.32)	< 0.001
IIIB	2.85 (2.39-3.40)	< 0.001	3.31 (2.76-3.96)	< 0.001	3.75 (3.04-6.64)	< 0.001	4.22 (3.40-5.23)	< 0.001
IIIC	5.73 (4.85-6.77)	< 0.001	6.32 (5.31-7.52)	< 0.001	8.06 (6.58-9.88)	< 0.001	8.58 (6.97-10.57)	< 0.001
Grade
Well/moderately differentiated	Reference		Reference		Reference
Poorly/undifferentiated	1.52 (1.35-1.72)	< 0.001	1.19 (1.05-1.35)	0.007	1.70 (1.49-1.96)	< 0.001
Type of surgery
Partial gastrectomy	Reference		Reference		Reference		Reference
Total gastrectomy	1.40 (1.29-1.53)	< 0.001	1.28 (1.17-1.40)	< 0.001	1.43 (1.31-1.58)	< 0.001	1.24 (1.13-1.37)	< 0.001
Chemotherapy
No	Reference		Reference		Reference		Reference
Yes	0.56 (0.51-0.61)	< 0.001	0.63 (0.56-0.70)	< 0.001	0.61 (0.55-0.67)	< 0.001	0.66 (0.89-0.74)	< 0.001
Neoadjuvant chemotherapy
No	Reference		Reference		Reference		Reference
Yes	0.71 (0.62-0.81)	< 0.001	1.48 (1.35-1.63)	< 0.001	0.76 (0.66-0.87)	< 0.001	1.33 (1.20-1.48)	< 0.001
Radiotherapy
No	Reference		Reference		Reference		Reference
Yes	0.64 (0.59-0.70)	< 0.001	0.77 (0.69-0.86)	< 0.001	0.67 (0.61-0.73)	< 0.001	0.76 (0.68-0.85)	< 0.001
Number of retrieved lymph nodes
ALA	Reference		Reference		Reference		Reference
OLA	0.81 (0.75-0.89)	< 0.001	0.71 (0.65-0.78)	< 0.001	0.84 (0.76-0.92)	< 0.001	0.74 (0.67-0.82)	< 0.001

¹Forward selection model. ADC: Adenocarcinoma; ALA: Adequate lymph node assessment; ILA: Inadequate lymph node assessment; NA: Not available, NOS: Not otherwise specified; OLA: Optimal lymph node assessment.